| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cyclin-Dependent Kinase 8 | 13 | 2022 | 15 | 4.770 |
Why?
|
| Cyclin-Dependent Kinases | 9 | 2022 | 60 | 2.950 |
Why?
|
| Drug Resistance | 41 | 1999 | 223 | 1.900 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 14 | 2016 | 97 | 1.800 |
Why?
|
| Cellular Senescence | 15 | 2012 | 112 | 1.670 |
Why?
|
| Neoplasms | 19 | 2019 | 1664 | 1.520 |
Why?
|
| Antineoplastic Agents | 21 | 2022 | 1070 | 1.440 |
Why?
|
| Membrane Glycoproteins | 19 | 1993 | 370 | 1.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 18 | 2019 | 756 | 1.330 |
Why?
|
| Colonic Neoplasms | 7 | 2022 | 299 | 1.310 |
Why?
|
| Genes, Suppressor | 10 | 2003 | 10 | 1.190 |
Why?
|
| Breast Neoplasms | 12 | 2022 | 1533 | 1.120 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2022 | 331 | 1.100 |
Why?
|
| Drug Resistance, Multiple | 9 | 2001 | 56 | 1.080 |
Why?
|
| Tumor Cells, Cultured | 34 | 2007 | 852 | 0.890 |
Why?
|
| Gene Amplification | 20 | 1992 | 71 | 0.890 |
Why?
|
| NF-kappa B | 3 | 2019 | 432 | 0.870 |
Why?
|
| RNA, Small Interfering | 8 | 2015 | 434 | 0.840 |
Why?
|
| Cell Line, Tumor | 18 | 2022 | 1851 | 0.830 |
Why?
|
| Cyclin C | 2 | 2019 | 3 | 0.820 |
Why?
|
| Genetic Vectors | 8 | 2006 | 311 | 0.820 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2022 | 332 | 0.810 |
Why?
|
| Coatomer Protein | 2 | 2011 | 4 | 0.810 |
Why?
|
| Cell Cycle | 9 | 2011 | 312 | 0.800 |
Why?
|
| Cyclins | 5 | 2016 | 50 | 0.770 |
Why?
|
| Cell Division | 15 | 2006 | 541 | 0.720 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2016 | 231 | 0.710 |
Why?
|
| Humans | 126 | 2022 | 68549 | 0.710 |
Why?
|
| Animals | 62 | 2022 | 20880 | 0.640 |
Why?
|
| Gene Expression Regulation | 10 | 2017 | 1293 | 0.640 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 15 | 0.640 |
Why?
|
| Antibodies, Monoclonal | 10 | 2003 | 511 | 0.640 |
Why?
|
| Fibrosarcoma | 8 | 2007 | 21 | 0.620 |
Why?
|
| DNA, Neoplasm | 11 | 2011 | 95 | 0.620 |
Why?
|
| Mitosis | 5 | 2005 | 76 | 0.610 |
Why?
|
| Neoplasm Proteins | 7 | 2002 | 307 | 0.600 |
Why?
|
| Retroviridae | 9 | 1998 | 29 | 0.600 |
Why?
|
| Mice | 38 | 2022 | 8474 | 0.600 |
Why?
|
| Cell Line | 28 | 2011 | 1752 | 0.590 |
Why?
|
| Matrix Metalloproteinases | 1 | 2018 | 223 | 0.570 |
Why?
|
| RNA, Messenger | 23 | 2009 | 1663 | 0.520 |
Why?
|
| Apoptosis | 9 | 2011 | 1641 | 0.520 |
Why?
|
| Doxorubicin | 17 | 2007 | 231 | 0.500 |
Why?
|
| Biomarkers, Tumor | 3 | 2015 | 508 | 0.480 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 334 | 0.480 |
Why?
|
| DNA, Complementary | 10 | 2010 | 251 | 0.480 |
Why?
|
| DNA | 18 | 2010 | 597 | 0.470 |
Why?
|
| DNA Replication | 6 | 2016 | 167 | 0.470 |
Why?
|
| Suppression, Genetic | 5 | 2011 | 10 | 0.470 |
Why?
|
| Carrier Proteins | 7 | 2002 | 597 | 0.460 |
Why?
|
| Moloney murine leukemia virus | 3 | 1998 | 13 | 0.450 |
Why?
|
| Colchicine | 12 | 2001 | 48 | 0.450 |
Why?
|
| Carcinoma | 7 | 2010 | 215 | 0.450 |
Why?
|
| Cloning, Molecular | 14 | 2003 | 357 | 0.450 |
Why?
|
| Base Sequence | 27 | 2011 | 1015 | 0.450 |
Why?
|
| Gene Library | 8 | 2010 | 68 | 0.440 |
Why?
|
| DNA Damage | 4 | 2012 | 190 | 0.440 |
Why?
|
| Promoter Regions, Genetic | 10 | 2015 | 614 | 0.430 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2004 | 204 | 0.420 |
Why?
|
| Vinblastine | 15 | 2001 | 40 | 0.410 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2006 | 235 | 0.410 |
Why?
|
| Gene Expression | 11 | 2015 | 770 | 0.410 |
Why?
|
| Growth Inhibitors | 2 | 2002 | 33 | 0.400 |
Why?
|
| Transfection | 14 | 2009 | 782 | 0.400 |
Why?
|
| Protein Subunits | 1 | 2011 | 99 | 0.390 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 56 | 0.390 |
Why?
|
| Sequence Analysis, DNA | 2 | 2010 | 208 | 0.390 |
Why?
|
| Protein Biosynthesis | 3 | 2004 | 181 | 0.380 |
Why?
|
| HEK293 Cells | 4 | 2019 | 326 | 0.370 |
Why?
|
| Transcription Factors | 6 | 2018 | 753 | 0.370 |
Why?
|
| Gene Silencing | 2 | 2011 | 137 | 0.370 |
Why?
|
| Transcription, Genetic | 11 | 2020 | 562 | 0.370 |
Why?
|
| Polymerase Chain Reaction | 16 | 2017 | 492 | 0.340 |
Why?
|
| Longevity | 1 | 2009 | 59 | 0.330 |
Why?
|
| DNA Repair | 4 | 2004 | 127 | 0.320 |
Why?
|
| Etoposide | 4 | 2001 | 64 | 0.320 |
Why?
|
| 3T3 Cells | 9 | 2001 | 124 | 0.320 |
Why?
|
| RNA Interference | 4 | 2018 | 266 | 0.310 |
Why?
|
| Retinoids | 2 | 2006 | 122 | 0.310 |
Why?
|
| Luminescent Proteins | 2 | 1998 | 57 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 38 | 0.290 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2006 | 6 | 0.290 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 75 | 0.290 |
Why?
|
| Adherens Junctions | 1 | 2006 | 13 | 0.290 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2017 | 320 | 0.280 |
Why?
|
| DNA, Viral | 8 | 1996 | 114 | 0.280 |
Why?
|
| Methotrexate | 4 | 1996 | 91 | 0.280 |
Why?
|
| HeLa Cells | 7 | 2008 | 237 | 0.280 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2006 | 48 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2022 | 304 | 0.280 |
Why?
|
| Transcriptional Activation | 4 | 2018 | 226 | 0.280 |
Why?
|
| Cell Survival | 5 | 2019 | 901 | 0.280 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 84 | 0.280 |
Why?
|
| Cadherins | 1 | 2006 | 93 | 0.270 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2004 | 61 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 627 | 0.270 |
Why?
|
| Cell Cycle Proteins | 5 | 2018 | 230 | 0.270 |
Why?
|
| RNA, Antisense | 3 | 1995 | 25 | 0.260 |
Why?
|
| Molecular Biology | 1 | 2005 | 31 | 0.260 |
Why?
|
| Fibroblasts | 6 | 2010 | 902 | 0.250 |
Why?
|
| MicroRNAs | 3 | 2018 | 447 | 0.250 |
Why?
|
| Cell Movement | 2 | 2009 | 630 | 0.250 |
Why?
|
| Molecular Sequence Data | 16 | 1999 | 1446 | 0.250 |
Why?
|
| DNA Topoisomerases, Type II | 3 | 2011 | 13 | 0.250 |
Why?
|
| Quinolines | 3 | 2022 | 48 | 0.240 |
Why?
|
| Tretinoin | 2 | 2002 | 92 | 0.240 |
Why?
|
| Keratinocytes | 1 | 2004 | 68 | 0.230 |
Why?
|
| Genes, Viral | 5 | 1998 | 44 | 0.230 |
Why?
|
| Aging | 3 | 2010 | 911 | 0.230 |
Why?
|
| Mutation | 8 | 2020 | 1213 | 0.220 |
Why?
|
| Genes, Regulator | 1 | 2003 | 17 | 0.220 |
Why?
|
| Neovascularization, Physiologic | 1 | 2004 | 164 | 0.220 |
Why?
|
| Protein Conformation | 6 | 2018 | 362 | 0.220 |
Why?
|
| Aphidicolin | 2 | 2000 | 8 | 0.210 |
Why?
|
| Repressor Proteins | 2 | 2009 | 182 | 0.210 |
Why?
|
| Immunoblotting | 3 | 2007 | 254 | 0.210 |
Why?
|
| Nucleic Acid Hybridization | 15 | 2000 | 95 | 0.210 |
Why?
|
| Lymphocytes | 3 | 1992 | 228 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1745 | 0.210 |
Why?
|
| Flow Cytometry | 10 | 2011 | 489 | 0.210 |
Why?
|
| Serpins | 1 | 2004 | 205 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 239 | 0.210 |
Why?
|
| Molecular Structure | 2 | 2022 | 397 | 0.210 |
Why?
|
| Ubiquitins | 1 | 2002 | 22 | 0.200 |
Why?
|
| Ovarian Neoplasms | 4 | 1997 | 267 | 0.200 |
Why?
|
| Fenretinide | 1 | 2002 | 26 | 0.200 |
Why?
|
| Dibenzocycloheptenes | 2 | 2019 | 4 | 0.200 |
Why?
|
| Phosphorylation | 2 | 2019 | 1200 | 0.200 |
Why?
|
| Nucleic Acid Renaturation | 5 | 1989 | 6 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2002 | 475 | 0.200 |
Why?
|
| Binding Sites, Antibody | 1 | 2001 | 34 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2006 | 710 | 0.190 |
Why?
|
| Cell Membrane Permeability | 1 | 2001 | 59 | 0.190 |
Why?
|
| Adenosine Triphosphate | 5 | 2019 | 314 | 0.190 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2002 | 144 | 0.190 |
Why?
|
| Bacterial Proteins | 2 | 1996 | 244 | 0.180 |
Why?
|
| Cyclin B | 1 | 2000 | 4 | 0.180 |
Why?
|
| Protein Isoforms | 3 | 2012 | 246 | 0.180 |
Why?
|
| Neoplasm Transplantation | 3 | 2012 | 160 | 0.180 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2000 | 27 | 0.180 |
Why?
|
| K562 Cells | 4 | 2006 | 44 | 0.180 |
Why?
|
| Female | 22 | 2022 | 38021 | 0.180 |
Why?
|
| Genome | 1 | 2020 | 54 | 0.180 |
Why?
|
| Plasmids | 6 | 2006 | 258 | 0.180 |
Why?
|
| Thienopyridines | 1 | 2019 | 3 | 0.180 |
Why?
|
| Anabolic Agents | 1 | 2019 | 6 | 0.180 |
Why?
|
| Paclitaxel | 5 | 2019 | 140 | 0.180 |
Why?
|
| Gene Editing | 1 | 2020 | 33 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 170 | 0.180 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 35 | 0.170 |
Why?
|
| Autoantigens | 1 | 2000 | 91 | 0.170 |
Why?
|
| Transduction, Genetic | 5 | 2001 | 81 | 0.170 |
Why?
|
| Autophagy | 2 | 2012 | 208 | 0.170 |
Why?
|
| Globins | 4 | 1983 | 13 | 0.170 |
Why?
|
| Databases, Genetic | 1 | 2019 | 52 | 0.170 |
Why?
|
| Protein Binding | 9 | 2019 | 1027 | 0.170 |
Why?
|
| Genes | 7 | 1987 | 86 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2007 | 82 | 0.170 |
Why?
|
| ErbB Receptors | 1 | 2021 | 239 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 384 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 1 | 1999 | 84 | 0.160 |
Why?
|
| Zebrafish | 1 | 2019 | 187 | 0.160 |
Why?
|
| Encephalomyocarditis virus | 1 | 1998 | 1 | 0.160 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2018 | 17 | 0.160 |
Why?
|
| Down-Regulation | 5 | 2009 | 447 | 0.160 |
Why?
|
| Ribosomes | 1 | 1998 | 23 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 57 | 0.160 |
Why?
|
| Skin | 3 | 2010 | 451 | 0.150 |
Why?
|
| RNA, Neoplasm | 3 | 2011 | 76 | 0.150 |
Why?
|
| Sarcoma Viruses, Murine | 1 | 1997 | 2 | 0.150 |
Why?
|
| Virus Integration | 1 | 1997 | 5 | 0.150 |
Why?
|
| Mutagenesis, Insertional | 1 | 1997 | 24 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 135 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 241 | 0.140 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1996 | 38 | 0.140 |
Why?
|
| Phosphoproteins | 1 | 2018 | 202 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 214 | 0.140 |
Why?
|
| Green Fluorescent Proteins | 3 | 2006 | 200 | 0.140 |
Why?
|
| Chromosome Mapping | 8 | 1998 | 188 | 0.140 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1998 | 138 | 0.140 |
Why?
|
| Biological Assay | 2 | 2019 | 88 | 0.140 |
Why?
|
| Valine | 2 | 2001 | 43 | 0.140 |
Why?
|
| Binding Sites | 5 | 2019 | 631 | 0.140 |
Why?
|
| Luciferases | 3 | 2006 | 105 | 0.140 |
Why?
|
| Escherichia coli Proteins | 1 | 1996 | 64 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 65 | 0.140 |
Why?
|
| Cells, Cultured | 11 | 2016 | 2673 | 0.140 |
Why?
|
| Folic Acid Antagonists | 1 | 1996 | 20 | 0.140 |
Why?
|
| Glycine | 2 | 2001 | 89 | 0.140 |
Why?
|
| Genomic Instability | 1 | 2016 | 41 | 0.140 |
Why?
|
| Sarcoma | 2 | 2012 | 70 | 0.140 |
Why?
|
| DNA Primers | 5 | 2011 | 302 | 0.130 |
Why?
|
| Estrogens | 1 | 2017 | 173 | 0.130 |
Why?
|
| Structure-Activity Relationship | 4 | 2022 | 420 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 2 | 2009 | 114 | 0.130 |
Why?
|
| Androgens | 1 | 2015 | 41 | 0.130 |
Why?
|
| Protein Kinase C | 5 | 1999 | 270 | 0.130 |
Why?
|
| Biological Transport | 4 | 1997 | 210 | 0.130 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 34 | 0.130 |
Why?
|
| Fluorescent Dyes | 4 | 2000 | 191 | 0.130 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1996 | 120 | 0.130 |
Why?
|
| Models, Biological | 4 | 2012 | 981 | 0.130 |
Why?
|
| Antigen-Antibody Reactions | 3 | 2001 | 13 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2003 | 216 | 0.120 |
Why?
|
| Glioblastoma | 1 | 1997 | 219 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2019 | 88 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 1989 | 18 | 0.120 |
Why?
|
| Butyrates | 1 | 1993 | 14 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2018 | 7028 | 0.110 |
Why?
|
| Substrate Specificity | 3 | 2022 | 234 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2012 | 682 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1993 | 5 | 0.110 |
Why?
|
| Cytokines | 1 | 2017 | 866 | 0.110 |
Why?
|
| Antigens, CD | 2 | 1996 | 230 | 0.110 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 301 | 0.110 |
Why?
|
| Chickens | 4 | 1983 | 232 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2015 | 2689 | 0.110 |
Why?
|
| Cell Nucleolus | 1 | 2012 | 14 | 0.110 |
Why?
|
| Phenotype | 5 | 2001 | 946 | 0.110 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2012 | 9 | 0.110 |
Why?
|
| Genes, Dominant | 1 | 1992 | 51 | 0.100 |
Why?
|
| DNA Restriction Enzymes | 11 | 1987 | 49 | 0.100 |
Why?
|
| Diglycerides | 1 | 1992 | 49 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 2791 | 0.100 |
Why?
|
| Glycerol | 1 | 1992 | 26 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 84 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2011 | 167 | 0.100 |
Why?
|
| Genomics | 1 | 2012 | 168 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2010 | 161 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1991 | 268 | 0.100 |
Why?
|
| RNA, Untranslated | 2 | 2009 | 11 | 0.100 |
Why?
|
| HCT116 Cells | 2 | 2012 | 63 | 0.100 |
Why?
|
| Glycoproteins | 3 | 1987 | 238 | 0.100 |
Why?
|
| Golgi Apparatus | 1 | 2011 | 75 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 778 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2550 | 0.090 |
Why?
|
| Shaker Superfamily of Potassium Channels | 1 | 2010 | 1 | 0.090 |
Why?
|
| KB Cells | 6 | 1990 | 9 | 0.090 |
Why?
|
| Nucleic Acid Conformation | 2 | 2009 | 92 | 0.090 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 17 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 196 | 0.090 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 3 | 1996 | 37 | 0.090 |
Why?
|
| Adenosine Triphosphatases | 4 | 2018 | 83 | 0.090 |
Why?
|
| Amino Acid Substitution | 2 | 2001 | 137 | 0.090 |
Why?
|
| Genes, MDR | 4 | 1998 | 9 | 0.090 |
Why?
|
| Hydrolysis | 4 | 2019 | 144 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 1991 | 274 | 0.090 |
Why?
|
| Lentivirus | 1 | 2010 | 35 | 0.090 |
Why?
|
| Genetic Engineering | 1 | 2010 | 41 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 261 | 0.090 |
Why?
|
| Genetic Techniques | 1 | 2010 | 32 | 0.090 |
Why?
|
| Adenine Nucleotides | 2 | 2001 | 11 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 271 | 0.090 |
Why?
|
| Proteins | 2 | 2004 | 473 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 4 | 2022 | 532 | 0.090 |
Why?
|
| Genes, p53 | 2 | 2001 | 41 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 2 | 2006 | 86 | 0.090 |
Why?
|
| Italy | 1 | 2009 | 36 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 499 | 0.080 |
Why?
|
| Multigene Family | 1 | 1989 | 93 | 0.080 |
Why?
|
| Organic Chemicals | 2 | 2000 | 77 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 91 | 0.080 |
Why?
|
| Blotting, Western | 5 | 2017 | 954 | 0.080 |
Why?
|
| Genes, ras | 1 | 1989 | 46 | 0.080 |
Why?
|
| Cytarabine | 3 | 1998 | 44 | 0.080 |
Why?
|
| Haplotypes | 1 | 2009 | 174 | 0.080 |
Why?
|
| Escherichia coli | 4 | 1998 | 368 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 21 | 0.080 |
Why?
|
| Cryoelectron Microscopy | 2 | 2019 | 9 | 0.080 |
Why?
|
| Amino Acid Sequence | 7 | 1998 | 1082 | 0.080 |
Why?
|
| SUMO-1 Protein | 1 | 2008 | 5 | 0.080 |
Why?
|
| Endopeptidases | 1 | 2008 | 52 | 0.080 |
Why?
|
| Oncogenes | 1 | 1988 | 71 | 0.080 |
Why?
|
| Mice, Nude | 2 | 1999 | 294 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2012 | 718 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 107 | 0.070 |
Why?
|
| Time Factors | 3 | 2006 | 4655 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2007 | 24 | 0.070 |
Why?
|
| Biomarkers | 2 | 2006 | 1593 | 0.070 |
Why?
|
| Leupeptins | 1 | 2007 | 23 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 51 | 0.070 |
Why?
|
| Adenoviruses, Human | 3 | 1982 | 12 | 0.070 |
Why?
|
| Mitochondria | 1 | 2012 | 643 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1998 | 77 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 1998 | 742 | 0.070 |
Why?
|
| RNA Stability | 1 | 2006 | 55 | 0.070 |
Why?
|
| Cricetinae | 6 | 1995 | 262 | 0.070 |
Why?
|
| Gene Transfer Techniques | 2 | 1997 | 173 | 0.070 |
Why?
|
| Exons | 2 | 2020 | 122 | 0.070 |
Why?
|
| USSR | 1 | 2005 | 2 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2003 | 111 | 0.070 |
Why?
|
| Viral Proteins | 2 | 1992 | 149 | 0.070 |
Why?
|
| Cell Death | 2 | 2012 | 329 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2005 | 91 | 0.060 |
Why?
|
| Actins | 1 | 2006 | 249 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2005 | 126 | 0.060 |
Why?
|
| Sulindac | 1 | 2004 | 4 | 0.060 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2004 | 6 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2004 | 28 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 47 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2005 | 248 | 0.060 |
Why?
|
| Culture Techniques | 1 | 2004 | 65 | 0.060 |
Why?
|
| Kinetics | 3 | 1996 | 1047 | 0.060 |
Why?
|
| Gamma Rays | 3 | 2001 | 64 | 0.060 |
Why?
|
| Genetic Markers | 3 | 1997 | 144 | 0.060 |
Why?
|
| Proteomics | 1 | 2006 | 246 | 0.060 |
Why?
|
| Chick Embryo | 4 | 1996 | 379 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 2 | 1996 | 78 | 0.060 |
Why?
|
| Telomere | 1 | 2004 | 59 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 1172 | 0.060 |
Why?
|
| Genes, Bacterial | 1 | 1983 | 40 | 0.060 |
Why?
|
| Telomerase | 1 | 2004 | 85 | 0.060 |
Why?
|
| Cell Membrane | 4 | 2010 | 524 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2017 | 52 | 0.060 |
Why?
|
| Histones | 1 | 2004 | 111 | 0.060 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1983 | 8 | 0.060 |
Why?
|
| Male | 10 | 2020 | 37283 | 0.060 |
Why?
|
| Inhibitor of Growth Protein 1 | 1 | 2003 | 1 | 0.060 |
Why?
|
| Restriction Mapping | 4 | 1990 | 85 | 0.050 |
Why?
|
| Leukemia, T-Cell | 3 | 1998 | 21 | 0.050 |
Why?
|
| Indicators and Reagents | 2 | 1997 | 63 | 0.050 |
Why?
|
| Bone Marrow | 2 | 1995 | 168 | 0.050 |
Why?
|
| Cyclosporine | 2 | 2000 | 121 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2022 | 17 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 700 | 0.050 |
Why?
|
| Carcinogens | 2 | 1998 | 86 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 1997 | 1174 | 0.050 |
Why?
|
| Biological Availability | 1 | 2022 | 79 | 0.050 |
Why?
|
| Simian virus 40 | 2 | 1978 | 24 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2022 | 546 | 0.050 |
Why?
|
| Arabidopsis Proteins | 1 | 2001 | 13 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 46 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 128 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 78 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 194 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2001 | 78 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2001 | 48 | 0.050 |
Why?
|
| Isoleucine | 1 | 2001 | 7 | 0.050 |
Why?
|
| Hemolysin Proteins | 1 | 2001 | 9 | 0.050 |
Why?
|
| Asparagine | 1 | 2001 | 15 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2001 | 55 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 223 | 0.050 |
Why?
|
| Leukemia | 1 | 2022 | 117 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 108 | 0.050 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2021 | 12 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2001 | 66 | 0.050 |
Why?
|
| Cetuximab | 1 | 2021 | 19 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1991 | 282 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2001 | 50 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2021 | 73 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2002 | 1692 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2000 | 7 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 22 | 0.050 |
Why?
|
| Cyclosporins | 1 | 2000 | 10 | 0.050 |
Why?
|
| Genetic Variation | 2 | 1997 | 220 | 0.050 |
Why?
|
| Cell Communication | 1 | 2001 | 116 | 0.050 |
Why?
|
| Deoxyribonucleoproteins | 1 | 1980 | 2 | 0.050 |
Why?
|
| Blotting, Southern | 2 | 1991 | 67 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 1980 | 6 | 0.050 |
Why?
|
| Centromere Protein A | 1 | 2000 | 2 | 0.050 |
Why?
|
| Isopropyl Thiogalactoside | 1 | 2000 | 6 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2000 | 7 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 1 | 2000 | 13 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2020 | 34 | 0.050 |
Why?
|
| Radiation, Ionizing | 1 | 2000 | 37 | 0.050 |
Why?
|
| Fungal Proteins | 1 | 2000 | 37 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2020 | 107 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 41 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 175 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 99 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1990 | 95 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 375 | 0.040 |
Why?
|
| Hydroxyurea | 2 | 1999 | 57 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 174 | 0.040 |
Why?
|
| Ploidies | 1 | 1999 | 6 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1999 | 43 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2000 | 102 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2000 | 122 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 61 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 1999 | 88 | 0.040 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2019 | 2 | 0.040 |
Why?
|
| DNA, Antisense | 1 | 1999 | 9 | 0.040 |
Why?
|
| Clone Cells | 2 | 1996 | 67 | 0.040 |
Why?
|
| Hair | 1 | 1999 | 46 | 0.040 |
Why?
|
| Polyomaviridae | 1 | 1978 | 2 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 1992 | 467 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 74 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2019 | 145 | 0.040 |
Why?
|
| Phospholipids | 1 | 2019 | 108 | 0.040 |
Why?
|
| Gout Suppressants | 1 | 1998 | 7 | 0.040 |
Why?
|
| Kanamycin Kinase | 1 | 1998 | 2 | 0.040 |
Why?
|
| Microtubules | 1 | 1999 | 104 | 0.040 |
Why?
|
| Gels | 2 | 1989 | 55 | 0.040 |
Why?
|
| Drug Design | 1 | 2019 | 107 | 0.040 |
Why?
|
| Alcohol Oxidoreductases | 1 | 1998 | 31 | 0.040 |
Why?
|
| Acetyltransferases | 1 | 1998 | 49 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 121 | 0.040 |
Why?
|
| Vault Ribonucleoprotein Particles | 1 | 1998 | 1 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2000 | 498 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 1978 | 87 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 1998 | 29 | 0.040 |
Why?
|
| Leukemia, Experimental | 1 | 1998 | 14 | 0.040 |
Why?
|
| Leukemia, Myeloid | 2 | 1987 | 39 | 0.040 |
Why?
|
| Mammals | 1 | 1998 | 47 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1999 | 308 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2018 | 128 | 0.040 |
Why?
|
| Adenoviridae | 1 | 1978 | 295 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 411 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 2018 | 80 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1174 | 0.040 |
Why?
|
| Epitopes | 1 | 2018 | 146 | 0.040 |
Why?
|
| Organoids | 1 | 1997 | 42 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1997 | 28 | 0.040 |
Why?
|
| Cholesterol | 1 | 2019 | 331 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 122 | 0.040 |
Why?
|
| Enzyme Inhibitors | 3 | 1998 | 659 | 0.040 |
Why?
|
| HIV-1 | 1 | 1999 | 177 | 0.040 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1997 | 6 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1997 | 20 | 0.040 |
Why?
|
| Galactosides | 1 | 1996 | 5 | 0.040 |
Why?
|
| Avian Sarcoma Viruses | 1 | 1996 | 20 | 0.040 |
Why?
|
| Lac Repressors | 1 | 1996 | 3 | 0.040 |
Why?
|
| Ligands | 1 | 2018 | 317 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 1999 | 291 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2001 | 597 | 0.040 |
Why?
|
| Proviruses | 1 | 1996 | 8 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 1999 | 211 | 0.040 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1998 | 200 | 0.030 |
Why?
|
| Staurosporine | 2 | 1997 | 19 | 0.030 |
Why?
|
| Molecular Weight | 4 | 1990 | 358 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 63 | 0.030 |
Why?
|
| Reference Values | 2 | 1999 | 579 | 0.030 |
Why?
|
| Phleomycins | 1 | 1996 | 2 | 0.030 |
Why?
|
| Surface-Active Agents | 1 | 1996 | 57 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1996 | 191 | 0.030 |
Why?
|
| Cisplatin | 1 | 1997 | 192 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1996 | 133 | 0.030 |
Why?
|
| Estradiol | 1 | 2017 | 176 | 0.030 |
Why?
|
| Biological Evolution | 2 | 1990 | 86 | 0.030 |
Why?
|
| Fatty Acids | 1 | 1996 | 222 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 1996 | 149 | 0.030 |
Why?
|
| Bacteriophages | 1 | 1995 | 24 | 0.030 |
Why?
|
| T-Phages | 2 | 1987 | 4 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1996 | 250 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 164 | 0.030 |
Why?
|
| Genotype | 2 | 2012 | 785 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 1987 | 35 | 0.030 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cricetulus | 4 | 1995 | 98 | 0.030 |
Why?
|
| RNA, Viral | 2 | 1992 | 93 | 0.030 |
Why?
|
| Pyrimidines | 1 | 1996 | 178 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1996 | 397 | 0.030 |
Why?
|
| Biological Transport, Active | 2 | 2000 | 49 | 0.030 |
Why?
|
| Oligonucleotide Probes | 2 | 1991 | 35 | 0.030 |
Why?
|
| Aged | 6 | 2010 | 14842 | 0.030 |
Why?
|
| Butyric Acid | 1 | 1993 | 4 | 0.030 |
Why?
|
| Species Specificity | 2 | 1995 | 302 | 0.030 |
Why?
|
| Transformation, Genetic | 2 | 1986 | 14 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 35 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 507 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1992 | 16 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1993 | 63 | 0.030 |
Why?
|
| United States | 1 | 2005 | 7338 | 0.030 |
Why?
|
| Melanoma | 2 | 1993 | 335 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1992 | 53 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1992 | 71 | 0.030 |
Why?
|
| Porins | 1 | 1992 | 3 | 0.030 |
Why?
|
| Bacteriophage lambda | 1 | 1992 | 7 | 0.030 |
Why?
|
| Deoxyguanosine | 1 | 2012 | 4 | 0.030 |
Why?
|
| Rhodamine 123 | 1 | 1992 | 13 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 1992 | 20 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1992 | 21 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 1992 | 49 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| Rhodamines | 1 | 1992 | 27 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2011 | 8 | 0.030 |
Why?
|
| Alkaloids | 1 | 1992 | 40 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1992 | 66 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1037 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 196 | 0.020 |
Why?
|
| Doxycycline | 1 | 2011 | 49 | 0.020 |
Why?
|
| Cytosine | 2 | 2009 | 12 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1989 | 44 | 0.020 |
Why?
|
| Poliovirus | 1 | 1991 | 4 | 0.020 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 1991 | 2 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 1991 | 10 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 280 | 0.020 |
Why?
|
| Kv1.1 Potassium Channel | 1 | 2010 | 1 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 146 | 0.020 |
Why?
|
| RNA | 1 | 1991 | 171 | 0.020 |
Why?
|
| Cosmids | 1 | 1990 | 2 | 0.020 |
Why?
|
| Lysine Carboxypeptidase | 1 | 1990 | 2 | 0.020 |
Why?
|
| Carboxypeptidases | 1 | 1990 | 8 | 0.020 |
Why?
|
| Mad2 Proteins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Leucine | 1 | 1990 | 41 | 0.020 |
Why?
|
| Introns | 1 | 1990 | 68 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2009 | 13 | 0.020 |
Why?
|
| Electrophoresis | 2 | 1989 | 69 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1991 | 369 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 1986 | 181 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2000 | 624 | 0.020 |
Why?
|
| Verapamil | 2 | 2000 | 30 | 0.020 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 2 | 1986 | 9 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1992 | 300 | 0.020 |
Why?
|
| Codon | 1 | 1989 | 21 | 0.020 |
Why?
|
| Base Composition | 1 | 2009 | 22 | 0.020 |
Why?
|
| Guanine | 1 | 2009 | 21 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 37 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1989 | 41 | 0.020 |
Why?
|
| Myeloproliferative Disorders | 1 | 1989 | 11 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 4843 | 0.020 |
Why?
|
| Enzyme Repression | 1 | 2008 | 3 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1991 | 1040 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1989 | 86 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 39 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 1987 | 24 | 0.020 |
Why?
|
| Karyotyping | 1 | 1987 | 74 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1987 | 32 | 0.020 |
Why?
|
| Haploidy | 1 | 1986 | 2 | 0.020 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 1986 | 2 | 0.020 |
Why?
|
| DNA, Recombinant | 2 | 1986 | 25 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1986 | 90 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 1986 | 62 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2006 | 272 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 1999 | 791 | 0.020 |
Why?
|
| G2 Phase | 1 | 2005 | 26 | 0.020 |
Why?
|
| Polyploidy | 1 | 2005 | 24 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 25 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1860 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 284 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 90 | 0.020 |
Why?
|
| Chemical Phenomena | 2 | 1990 | 62 | 0.020 |
Why?
|
| Demecolcine | 1 | 1984 | 1 | 0.020 |
Why?
|
| Vincristine | 2 | 1999 | 44 | 0.020 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1983 | 29 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1983 | 26 | 0.010 |
Why?
|
| Ovary | 1 | 1984 | 99 | 0.010 |
Why?
|
| Peptide Hydrolases | 2 | 1982 | 82 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1983 | 30 | 0.010 |
Why?
|
| Enterobacteriaceae | 1 | 1983 | 29 | 0.010 |
Why?
|
| Calcium | 2 | 1999 | 929 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1983 | 4 | 0.010 |
Why?
|
| Endonucleases | 1 | 1983 | 10 | 0.010 |
Why?
|
| Tyrosine | 2 | 1982 | 196 | 0.010 |
Why?
|
| Hormones | 1 | 1983 | 42 | 0.010 |
Why?
|
| Survival Rate | 2 | 1997 | 1055 | 0.010 |
Why?
|
| Adolescent | 2 | 2010 | 8904 | 0.010 |
Why?
|
| Spermatogenesis | 1 | 2001 | 7 | 0.010 |
Why?
|
| Spermatozoa | 1 | 1982 | 75 | 0.010 |
Why?
|
| Adult | 4 | 2010 | 21379 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 35 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1982 | 137 | 0.010 |
Why?
|
| Fetal Hemoglobin | 1 | 1981 | 10 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2001 | 60 | 0.010 |
Why?
|
| Testis | 1 | 2001 | 37 | 0.010 |
Why?
|
| fas Receptor | 1 | 2001 | 54 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2001 | 97 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 160 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 119 | 0.010 |
Why?
|
| Glycosylation | 2 | 1993 | 185 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1982 | 120 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1982 | 765 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2001 | 150 | 0.010 |
Why?
|
| Daunorubicin | 1 | 2000 | 20 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 386 | 0.010 |
Why?
|
| Point Mutation | 1 | 2000 | 97 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1992 | 7268 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2000 | 137 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2001 | 222 | 0.010 |
Why?
|
| Coliphages | 1 | 1979 | 6 | 0.010 |
Why?
|
| Body Weight | 1 | 2001 | 554 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2001 | 195 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1999 | 24 | 0.010 |
Why?
|
| Lung | 1 | 1984 | 849 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 5710 | 0.010 |
Why?
|
| Nocodazole | 1 | 1999 | 11 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1999 | 29 | 0.010 |
Why?
|
| Genome, Viral | 1 | 1999 | 14 | 0.010 |
Why?
|
| Chemistry | 1 | 1978 | 45 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 626 | 0.010 |
Why?
|
| Ethylmaleimide | 1 | 1998 | 9 | 0.010 |
Why?
|
| Catalysis | 1 | 1978 | 123 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1998 | 31 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 230 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1998 | 50 | 0.010 |
Why?
|
| Virus Replication | 1 | 1978 | 104 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1998 | 130 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1997 | 28 | 0.010 |
Why?
|
| Electricity | 1 | 1997 | 33 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1997 | 50 | 0.010 |
Why?
|
| Cytosol | 1 | 1997 | 123 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1997 | 349 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1996 | 16 | 0.010 |
Why?
|
| Macromolecular Substances | 2 | 1990 | 122 | 0.010 |
Why?
|
| Vanadates | 1 | 1996 | 12 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1996 | 140 | 0.010 |
Why?
|
| Spodoptera | 1 | 1996 | 21 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1996 | 66 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1996 | 126 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1995 | 94 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1753 | 0.010 |
Why?
|
| CHO Cells | 1 | 1995 | 161 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1995 | 149 | 0.010 |
Why?
|
| Prognosis | 1 | 1997 | 2093 | 0.010 |
Why?
|
| Middle Aged | 3 | 1997 | 21119 | 0.010 |
Why?
|
| Animal Testing Alternatives | 1 | 1991 | 5 | 0.010 |
Why?
|
| Haplorhini | 1 | 1991 | 44 | 0.010 |
Why?
|
| Brain | 1 | 1982 | 2176 | 0.010 |
Why?
|
| Chemistry, Physical | 1 | 1990 | 21 | 0.010 |
Why?
|
| DNA Probes | 1 | 1989 | 57 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1989 | 27 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1989 | 25 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1989 | 31 | 0.010 |
Why?
|
| Blast Crisis | 1 | 1987 | 7 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1989 | 172 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1986 | 31 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1986 | 18 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1986 | 17 | 0.000 |
Why?
|
| Child | 1 | 1997 | 6401 | 0.000 |
Why?
|
| Kidney | 1 | 1991 | 945 | 0.000 |
Why?
|
| Mitogens | 1 | 1983 | 45 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1982 | 351 | 0.000 |
Why?
|
| 5-Methylcytosine | 1 | 1982 | 3 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1982 | 119 | 0.000 |
Why?
|
| Methylation | 1 | 1982 | 56 | 0.000 |
Why?
|
| Mouth Neoplasms | 1 | 1982 | 206 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1982 | 483 | 0.000 |
Why?
|
| Insulin | 1 | 1983 | 617 | 0.000 |
Why?
|